APO Research
Talk to an analyst

APO RESEARCH · REPORT

Single-target Anti-VEGF Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Single-target Anti-VEGF Drugs Market Analysis and Forecast 2026-2032

27 December 2025197 pages

Choose your research edition.

Industry ResearchSingle-target Anti-VEGF Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Single-target Anti-VEGF Drugs Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Single-target Anti-VEGF Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Single-target Anti-VEGF Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Single-target Anti-VEGF Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Single-target Anti-VEGF Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Single-target Anti-VEGF Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Single-target Anti-VEGF Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Single-target Anti-VEGF Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Single-target Anti-VEGF Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Single-target Anti-VEGF Drugs include Roche, Chengdu Kanghong Pharmaceutical, Samsung Bioepis, Regeneron Pharmaceuticals, Novartis, Coherus BioSciences and Biocon Biologics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Single-target Anti-VEGF Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Single-target Anti-VEGF Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Single-target Anti-VEGF Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Single-target Anti-VEGF Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Single-target Anti-VEGF Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Single-target Anti-VEGF Drugs sales, projected growth trends, production technology, application and end-user industry.

Single-target Anti-VEGF Drugs Segment by Company

Roche

Chengdu Kanghong Pharmaceutical

Samsung Bioepis

Regeneron Pharmaceuticals

Novartis

Coherus BioSciences

Biocon Biologics

Single-target Anti-VEGF Drugs Segment by Type

Ranibizumab

Conbercept

Faricimab

Brolucizumab

Aflibercept

Other

Single-target Anti-VEGF Drugs Segment by Application

Diabetic Retinopathy

Age-related Macular Degeneration

Other

Single-target Anti-VEGF Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Single-target Anti-VEGF Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Single-target Anti-VEGF Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Single-target Anti-VEGF Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Single-target Anti-VEGF Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Single-target Anti-VEGF Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Single-target Anti-VEGF Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Single-target Anti-VEGF Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Ranibizumab Major Manufacturers Table 3. Conbercept Major Manufacturers Table 4. Faricimab Major Manufacturers Table 5. Brolucizumab Major Manufacturers Table 6. Aflibercept Major Manufacturers Table 7. Other Major Manufacturers Table 8. Global Single-target Anti-VEGF Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Diabetic Retinopathy Major Manufacturers Table 10. Age-related Macular Degeneration Major Manufacturers Table 11. Other Major Manufacturers Table 12. Single-target Anti-VEGF Drugs Industry Trends Table 13. Single-target Anti-VEGF Drugs Industry Drivers Table 14. Single-target Anti-VEGF Drugs Industry Opportunities and Challenges Table 15. Single-target Anti-VEGF Drugs Industry Restraints Table 16. Global Single-target Anti-VEGF Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Single-target Anti-VEGF Drugs Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Single-target Anti-VEGF Drugs Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Single-target Anti-VEGF Drugs Revenue Market Share by Region (2021-2026) Table 20. Global Single-target Anti-VEGF Drugs Revenue Market Share by Region (2027-2032) Table 21. Global Single-target Anti-VEGF Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 22. Global Single-target Anti-VEGF Drugs Sales by Region (2021-2026) & (K Units) Table 23. Global Single-target Anti-VEGF Drugs Sales by Region (2027-2032) & (K Units) Table 24. Global Single-target Anti-VEGF Drugs Sales Market Share by Region (2021-2026) Table 25. Global Single-target Anti-VEGF Drugs Sales Market Share by Region (2027-2032) Table 26. Global Single-target Anti-VEGF Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Single-target Anti-VEGF Drugs Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Single-target Anti-VEGF Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Single-target Anti-VEGF Drugs Sales Market Share by Manufacturers (2021-2026) Table 30. Global Single-target Anti-VEGF Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global Single-target Anti-VEGF Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Single-target Anti-VEGF Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Single-target Anti-VEGF Drugs Manufacturers, Product Type & Application Table 34. Global Single-target Anti-VEGF Drugs Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Single-target Anti-VEGF Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Single-target Anti-VEGF Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Single-target Anti-VEGF Drugs Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Single-target Anti-VEGF Drugs Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2021-2026) Table 41. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2027-2032) Table 42. Global Single-target Anti-VEGF Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 43. Global Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units) Table 44. Global Single-target Anti-VEGF Drugs Sales by Type (2027-2032) & (K Units) Table 45. Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2021-2026) Table 46. Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2027-2032) Table 47. Global Single-target Anti-VEGF Drugs Price by Type (2021-2026) & (US$/Unit) Table 48. Global Single-target Anti-VEGF Drugs Price by Type (2027-2032) & (US$/Unit) Table 49. Global Single-target Anti-VEGF Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Single-target Anti-VEGF Drugs Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Single-target Anti-VEGF Drugs Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2021-2026) Table 53. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2027-2032) Table 54. Global Single-target Anti-VEGF Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 55. Global Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units) Table 56. Global Single-target Anti-VEGF Drugs Sales by Application (2027-2032) & (K Units) Table 57. Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2021-2026) Table 58. Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2027-2032) Table 59. Global Single-target Anti-VEGF Drugs Price by Application (2021-2026) & (US$/Unit) Table 60. Global Single-target Anti-VEGF Drugs Price by Application (2027-2032) & (US$/Unit) Table 61. Roche Company Information Table 62. Roche Business Overview Table 63. Roche Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Roche Single-target Anti-VEGF Drugs Product Portfolio Table 65. Roche Recent Development Table 66. Chengdu Kanghong Pharmaceutical Company Information Table 67. Chengdu Kanghong Pharmaceutical Business Overview Table 68. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product Portfolio Table 70. Chengdu Kanghong Pharmaceutical Recent Development Table 71. Samsung Bioepis Company Information Table 72. Samsung Bioepis Business Overview Table 73. Samsung Bioepis Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Samsung Bioepis Single-target Anti-VEGF Drugs Product Portfolio Table 75. Samsung Bioepis Recent Development Table 76. Regeneron Pharmaceuticals Company Information Table 77. Regeneron Pharmaceuticals Business Overview Table 78. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product Portfolio Table 80. Regeneron Pharmaceuticals Recent Development Table 81. Novartis Company Information Table 82. Novartis Business Overview Table 83. Novartis Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Novartis Single-target Anti-VEGF Drugs Product Portfolio Table 85. Novartis Recent Development Table 86. Coherus BioSciences Company Information Table 87. Coherus BioSciences Business Overview Table 88. Coherus BioSciences Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Coherus BioSciences Single-target Anti-VEGF Drugs Product Portfolio Table 90. Coherus BioSciences Recent Development Table 91. Biocon Biologics Company Information Table 92. Biocon Biologics Business Overview Table 93. Biocon Biologics Single-target Anti-VEGF Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Biocon Biologics Single-target Anti-VEGF Drugs Product Portfolio Table 95. Biocon Biologics Recent Development Table 96. North America Single-target Anti-VEGF Drugs Revenue by Type (2021-2026) & (US$ Million) Table 97. North America Single-target Anti-VEGF Drugs Revenue by Type (2027-2032) & (US$ Million) Table 98. North America Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units) Table 99. North America Single-target Anti-VEGF Drugs Sales by Type (2027-2032) & (K Units) Table 100. North America Single-target Anti-VEGF Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 101. North America Single-target Anti-VEGF Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 102. North America Single-target Anti-VEGF Drugs Revenue by Application (2021-2026) & (US$ Million) Table 103. North America Single-target Anti-VEGF Drugs Revenue by Application (2027-2032) & (US$ Million) Table 104. North America Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units) Table 105. North America Single-target Anti-VEGF Drugs Sales by Application (2027-2032) & (K Units) Table 106. North America Single-target Anti-VEGF Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 107. North America Single-target Anti-VEGF Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 108. North America Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. North America Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 110. North America Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 111. North America Single-target Anti-VEGF Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 112. North America Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 113. North America Single-target Anti-VEGF Drugs Sales by Country (2027-2032) & (K Units) Table 114. North America Single-target Anti-VEGF Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 115. North America Single-target Anti-VEGF Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 116. United States Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 117. Canada Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 118. Mexico Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 119. Europe Single-target Anti-VEGF Drugs Revenue by Type (2021-2026) & (US$ Million) Table 120. Europe Single-target Anti-VEGF Drugs Revenue by Type (2027-2032) & (US$ Million) Table 121. Europe Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units) Table 122. Europe Single-target Anti-VEGF Drugs Sales by Type (2027-2032) & (K Units) Table 123. Europe Single-target Anti-VEGF Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 124. Europe Single-target Anti-VEGF Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 125. Europe Single-target Anti-VEGF Drugs Revenue by Application (2021-2026) & (US$ Million) Table 126. Europe Single-target Anti-VEGF Drugs Revenue by Application (2027-2032) & (US$ Million) Table 127. Europe Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units) Table 128. Europe Single-target Anti-VEGF Drugs Sales by Application (2027-2032) & (K Units) Table 129. Europe Single-target Anti-VEGF Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 130. Europe Single-target Anti-VEGF Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 131. Europe Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. Europe Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 133. Europe Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 134. Europe Single-target Anti-VEGF Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 135. Europe Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 136. Europe Single-target Anti-VEGF Drugs Sales by Country (2027-2032) & (K Units) Table 137. Europe Single-target Anti-VEGF Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 138. Europe Single-target Anti-VEGF Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 139. Germany Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 140. France Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 141. U.K. Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 142. Italy Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 143. Russia Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 144. Spain Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 145. Netherlands Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 146. Switzerland Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 147. Sweden Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 148. Poland Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 149. China Single-target Anti-VEGF Drugs Revenue by Type (2021-2026) & (US$ Million) Table 150. China Single-target Anti-VEGF Drugs Revenue by Type (2027-2032) & (US$ Million) Table 151. China Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units) Table 152. China Single-target Anti-VEGF Drugs Sales by Type (2027-2032) & (K Units) Table 153. China Single-target Anti-VEGF Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 154. China Single-target Anti-VEGF Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 155. China Single-target Anti-VEGF Drugs Revenue by Application (2021-2026) & (US$ Million) Table 156. China Single-target Anti-VEGF Drugs Revenue by Application (2027-2032) & (US$ Million) Table 157. China Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units) Table 158. China Single-target Anti-VEGF Drugs Sales by Application (2027-2032) & (K Units) Table 159. China Single-target Anti-VEGF Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 160. China Single-target Anti-VEGF Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 161. Asia Single-target Anti-VEGF Drugs Revenue by Type (2021-2026) & (US$ Million) Table 162. Asia Single-target Anti-VEGF Drugs Revenue by Type (2027-2032) & (US$ Million) Table 163. Asia Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units) Table 164. Asia Single-target Anti-VEGF Drugs Sales by Type (2027-2032) & (K Units) Table 165. Asia Single-target Anti-VEGF Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 166. Asia Single-target Anti-VEGF Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 167. Asia Single-target Anti-VEGF Drugs Revenue by Application (2021-2026) & (US$ Million) Table 168. Asia Single-target Anti-VEGF Drugs Revenue by Application (2027-2032) & (US$ Million) Table 169. Asia Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units) Table 170. Asia Single-target Anti-VEGF Drugs Sales by Application (2027-2032) & (K Units) Table 171. Asia Single-target Anti-VEGF Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 172. Asia Single-target Anti-VEGF Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 173. Asia Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 174. Asia Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 175. Asia Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 176. Asia Single-target Anti-VEGF Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 177. Asia Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 178. Asia Single-target Anti-VEGF Drugs Sales by Country (2027-2032) & (K Units) Table 179. Asia Single-target Anti-VEGF Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 180. Asia Single-target Anti-VEGF Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 181. Japan Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 182. South Korea Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 183. India Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 184. Australia Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 185. Taiwan Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 186. Southeast Asia Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 187. SAMEA Single-target Anti-VEGF Drugs Revenue by Type (2021-2026) & (US$ Million) Table 188. SAMEA Single-target Anti-VEGF Drugs Revenue by Type (2027-2032) & (US$ Million) Table 189. SAMEA Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units) Table 190. SAMEA Single-target Anti-VEGF Drugs Sales by Type (2027-2032) & (K Units) Table 191. SAMEA Single-target Anti-VEGF Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 192. SAMEA Single-target Anti-VEGF Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 193. SAMEA Single-target Anti-VEGF Drugs Revenue by Application (2021-2026) & (US$ Million) Table 194. SAMEA Single-target Anti-VEGF Drugs Revenue by Application (2027-2032) & (US$ Million) Table 195. SAMEA Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units) Table 196. SAMEA Single-target Anti-VEGF Drugs Sales by Application (2027-2032) & (K Units) Table 197. SAMEA Single-target Anti-VEGF Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 198. SAMEA Single-target Anti-VEGF Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 199. SAMEA Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 200. SAMEA Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 201. SAMEA Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 202. SAMEA Single-target Anti-VEGF Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 203. SAMEA Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 204. SAMEA Single-target Anti-VEGF Drugs Sales by Country (2027-2032) & (K Units) Table 205. SAMEA Single-target Anti-VEGF Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 206. SAMEA Single-target Anti-VEGF Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 207. Brazil Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 208. Argentina Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 209. Chile Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 210. Colombia Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 211. Peru Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 212. Saudi Arabia Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 213. Israel Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 214. UAE Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 215. Turkey Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 216. Iran Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 217. Egypt Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Table 218. Key Raw Materials Table 219. Raw Materials Key Suppliers Table 220. Single-target Anti-VEGF Drugs Distributors List Table 221. Single-target Anti-VEGF Drugs Customers List Table 222. Research Programs/Design for This Report Table 223. Authors List of This Report Table 224. Secondary Sources Table 225. Primary Sources List of Figures Figure 1. Single-target Anti-VEGF Drugs Image Figure 2. Global Single-target Anti-VEGF Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Single-target Anti-VEGF Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Ranibizumab Image Figure 5. Conbercept Image Figure 6. Faricimab Image Figure 7. Brolucizumab Image Figure 8. Aflibercept Image Figure 9. Other Image Figure 10. Global Single-target Anti-VEGF Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Single-target Anti-VEGF Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 12. Diabetic Retinopathy Image Figure 13. Age-related Macular Degeneration Image Figure 14. Other Image Figure 15. Global Single-target Anti-VEGF Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Figure 17. Global Single-target Anti-VEGF Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Single-target Anti-VEGF Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Single-target Anti-VEGF Drugs Revenue Market Share by Region (2021-2032) Figure 20. Global Single-target Anti-VEGF Drugs Sales (2021-2032) & (K Units) Figure 21. Global Single-target Anti-VEGF Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 22. Global Single-target Anti-VEGF Drugs Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Single-target Anti-VEGF Drugs Sales YoY (2021-2032) & (K Units) Figure 24. Europe Single-target Anti-VEGF Drugs Sales YoY (2021-2032) & (K Units) Figure 25. China Single-target Anti-VEGF Drugs Sales YoY (2021-2032) & (K Units) Figure 26. Asia (Excluding China) Single-target Anti-VEGF Drugs Sales YoY (2021-2032) & (K Units) Figure 27. South America, Middle East and Africa Single-target Anti-VEGF Drugs Sales YoY (2021-2032) & (K Units) Figure 28. Global Single-target Anti-VEGF Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Single-target Anti-VEGF Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Single-target Anti-VEGF Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2021-2032) Figure 34. Global Single-target Anti-VEGF Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 35. Global Single-target Anti-VEGF Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2021-2032) Figure 37. Global Single-target Anti-VEGF Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2021-2032) Figure 40. Global Single-target Anti-VEGF Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 41. Global Single-target Anti-VEGF Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2021-2032) Figure 43. North America Single-target Anti-VEGF Drugs Revenue Share by Type (2021-2032) Figure 44. North America Single-target Anti-VEGF Drugs Sales Share by Type (2021-2032) Figure 45. North America Single-target Anti-VEGF Drugs Revenue Share by Application (2021-2032) Figure 46. North America Single-target Anti-VEGF Drugs Sales Share by Application (2021-2032) Figure 47. North America Single-target Anti-VEGF Drugs Revenue Share by Country (2021-2032) Figure 48. North America Single-target Anti-VEGF Drugs Sales Share by Country (2021-2032) Figure 49. Europe Single-target Anti-VEGF Drugs Revenue Share by Type (2021-2032) Figure 50. Europe Single-target Anti-VEGF Drugs Sales Share by Type (2021-2032) Figure 51. Europe Single-target Anti-VEGF Drugs Revenue Share by Application (2021-2032) Figure 52. Europe Single-target Anti-VEGF Drugs Sales Share by Application (2021-2032) Figure 53. Europe Single-target Anti-VEGF Drugs Revenue Share by Country (2021-2032) Figure 54. Europe Single-target Anti-VEGF Drugs Sales Share by Country (2021-2032) Figure 55. China Single-target Anti-VEGF Drugs Revenue Share by Type (2021-2032) Figure 56. China Single-target Anti-VEGF Drugs Sales Share by Type (2021-2032) Figure 57. China Single-target Anti-VEGF Drugs Revenue Share by Application (2021-2032) Figure 58. China Single-target Anti-VEGF Drugs Sales Share by Application (2021-2032) Figure 59. Asia Single-target Anti-VEGF Drugs Revenue Share by Type (2021-2032) Figure 60. Asia Single-target Anti-VEGF Drugs Sales Share by Type (2021-2032) Figure 61. Asia Single-target Anti-VEGF Drugs Revenue Share by Application (2021-2032) Figure 62. Asia Single-target Anti-VEGF Drugs Sales Share by Application (2021-2032) Figure 63. Asia Single-target Anti-VEGF Drugs Revenue Share by Country (2021-2032) Figure 64. Asia Single-target Anti-VEGF Drugs Sales Share by Country (2021-2032) Figure 65. SAMEA Single-target Anti-VEGF Drugs Revenue Share by Type (2021-2032) Figure 66. SAMEA Single-target Anti-VEGF Drugs Sales Share by Type (2021-2032) Figure 67. SAMEA Single-target Anti-VEGF Drugs Revenue Share by Application (2021-2032) Figure 68. SAMEA Single-target Anti-VEGF Drugs Sales Share by Application (2021-2032) Figure 69. SAMEA Single-target Anti-VEGF Drugs Revenue Share by Country (2021-2032) Figure 70. SAMEA Single-target Anti-VEGF Drugs Sales Share by Country (2021-2032) Figure 71. Single-target Anti-VEGF Drugs Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Single-target Anti-VEGF Drugs Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Ranibizumab
  • Conbercept
  • Faricimab
  • Brolucizumab
  • Aflibercept
  • Other
Applications
  • Diabetic Retinopathy
  • Age-related Macular Degeneration
  • Other
Companies covered
  • Roche
  • Chengdu Kanghong Pharmaceutical
  • Samsung Bioepis
  • Regeneron Pharmaceuticals
  • Novartis
  • Coherus BioSciences
  • Biocon Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Single-target Anti-VEGF Drugs Market by Type
  3. 1.2.1 Global Single-target Anti-VEGF Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Ranibizumab
  5. 1.2.3 Conbercept
  6. 1.2.4 Faricimab
  7. 1.2.5 Brolucizumab
  8. 1.2.6 Aflibercept
  9. 1.2.7 Other
  10. 1.3 Single-target Anti-VEGF Drugs Market by Application
  11. 1.3.1 Global Single-target Anti-VEGF Drugs Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Diabetic Retinopathy
  13. 1.3.3 Age-related Macular Degeneration
  14. 1.3.4 Other
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Single-target Anti-VEGF Drugs Market Dynamics
  1. 2.1 Single-target Anti-VEGF Drugs Industry Trends
  2. 2.2 Single-target Anti-VEGF Drugs Industry Drivers
  3. 2.3 Single-target Anti-VEGF Drugs Industry Opportunities and Challenges
  4. 2.4 Single-target Anti-VEGF Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Single-target Anti-VEGF Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Single-target Anti-VEGF Drugs Revenue by Region
  3. 3.2.1 Global Single-target Anti-VEGF Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Single-target Anti-VEGF Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Single-target Anti-VEGF Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Single-target Anti-VEGF Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Single-target Anti-VEGF Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Single-target Anti-VEGF Drugs Sales by Region
  9. 3.4.1 Global Single-target Anti-VEGF Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Single-target Anti-VEGF Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Single-target Anti-VEGF Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Single-target Anti-VEGF Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Single-target Anti-VEGF Drugs Revenue by Manufacturers
  2. 4.1.1 Global Single-target Anti-VEGF Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Single-target Anti-VEGF Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Single-target Anti-VEGF Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Single-target Anti-VEGF Drugs Sales by Manufacturers
  6. 4.2.1 Global Single-target Anti-VEGF Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Single-target Anti-VEGF Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Single-target Anti-VEGF Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Single-target Anti-VEGF Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Single-target Anti-VEGF Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Single-target Anti-VEGF Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Single-target Anti-VEGF Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Single-target Anti-VEGF Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Single-target Anti-VEGF Drugs Market CR5 and HHI
  16. 4.8.2 2025 Single-target Anti-VEGF Drugs Tier 1, Tier 2, and Tier 3
5 Single-target Anti-VEGF Drugs Market by Type
  1. 5.1 Global Single-target Anti-VEGF Drugs Revenue by Type
  2. 5.1.1 Global Single-target Anti-VEGF Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Single-target Anti-VEGF Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Single-target Anti-VEGF Drugs Sales by Type
  6. 5.2.1 Global Single-target Anti-VEGF Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Single-target Anti-VEGF Drugs Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Single-target Anti-VEGF Drugs Price by Type
6 Single-target Anti-VEGF Drugs Market by Application
  1. 6.1 Global Single-target Anti-VEGF Drugs Revenue by Application
  2. 6.1.1 Global Single-target Anti-VEGF Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Single-target Anti-VEGF Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Single-target Anti-VEGF Drugs Sales by Application
  6. 6.2.1 Global Single-target Anti-VEGF Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Single-target Anti-VEGF Drugs Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Single-target Anti-VEGF Drugs Price by Application
7 Company Profiles
  1. 7.1 Roche
  2. 7.1.1 Roche Company Information
  3. 7.1.2 Roche Business Overview
  4. 7.1.3 Roche Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Roche Single-target Anti-VEGF Drugs Product Portfolio
  6. 7.1.5 Roche Recent Developments
  7. 7.2 Chengdu Kanghong Pharmaceutical
  8. 7.2.1 Chengdu Kanghong Pharmaceutical Company Information
  9. 7.2.2 Chengdu Kanghong Pharmaceutical Business Overview
  10. 7.2.3 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product Portfolio
  12. 7.2.5 Chengdu Kanghong Pharmaceutical Recent Developments
  13. 7.3 Samsung Bioepis
  14. 7.3.1 Samsung Bioepis Company Information
  15. 7.3.2 Samsung Bioepis Business Overview
  16. 7.3.3 Samsung Bioepis Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Samsung Bioepis Single-target Anti-VEGF Drugs Product Portfolio
  18. 7.3.5 Samsung Bioepis Recent Developments
  19. 7.4 Regeneron Pharmaceuticals
  20. 7.4.1 Regeneron Pharmaceuticals Company Information
  21. 7.4.2 Regeneron Pharmaceuticals Business Overview
  22. 7.4.3 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product Portfolio
  24. 7.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 7.5 Novartis
  26. 7.5.1 Novartis Company Information
  27. 7.5.2 Novartis Business Overview
  28. 7.5.3 Novartis Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Novartis Single-target Anti-VEGF Drugs Product Portfolio
  30. 7.5.5 Novartis Recent Developments
  31. 7.6 Coherus BioSciences
  32. 7.6.1 Coherus BioSciences Company Information
  33. 7.6.2 Coherus BioSciences Business Overview
  34. 7.6.3 Coherus BioSciences Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Coherus BioSciences Single-target Anti-VEGF Drugs Product Portfolio
  36. 7.6.5 Coherus BioSciences Recent Developments
  37. 7.7 Biocon Biologics
  38. 7.7.1 Biocon Biologics Company Information
  39. 7.7.2 Biocon Biologics Business Overview
  40. 7.7.3 Biocon Biologics Single-target Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Biocon Biologics Single-target Anti-VEGF Drugs Product Portfolio
  42. 7.7.5 Biocon Biologics Recent Developments
8 North America
  1. 8.1 North America Single-target Anti-VEGF Drugs Market Size by Type
  2. 8.1.1 North America Single-target Anti-VEGF Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Single-target Anti-VEGF Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Single-target Anti-VEGF Drugs Price by Type (2021-2032)
  5. 8.2 North America Single-target Anti-VEGF Drugs Market Size by Application
  6. 8.2.1 North America Single-target Anti-VEGF Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Single-target Anti-VEGF Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Single-target Anti-VEGF Drugs Price by Application (2021-2032)
  9. 8.3 North America Single-target Anti-VEGF Drugs Market Size by Country
  10. 8.3.1 North America Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Single-target Anti-VEGF Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Single-target Anti-VEGF Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Single-target Anti-VEGF Drugs Market Size by Type
  2. 9.1.1 Europe Single-target Anti-VEGF Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Single-target Anti-VEGF Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Single-target Anti-VEGF Drugs Price by Type (2021-2032)
  5. 9.2 Europe Single-target Anti-VEGF Drugs Market Size by Application
  6. 9.2.1 Europe Single-target Anti-VEGF Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Single-target Anti-VEGF Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Single-target Anti-VEGF Drugs Price by Application (2021-2032)
  9. 9.3 Europe Single-target Anti-VEGF Drugs Market Size by Country
  10. 9.3.1 Europe Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Single-target Anti-VEGF Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Single-target Anti-VEGF Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Single-target Anti-VEGF Drugs Market Size by Type
  2. 10.1.1 China Single-target Anti-VEGF Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Single-target Anti-VEGF Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Single-target Anti-VEGF Drugs Price by Type (2021-2032)
  5. 10.2 China Single-target Anti-VEGF Drugs Market Size by Application
  6. 10.2.1 China Single-target Anti-VEGF Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Single-target Anti-VEGF Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Single-target Anti-VEGF Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Single-target Anti-VEGF Drugs Market Size by Type
  2. 11.1.1 Asia Single-target Anti-VEGF Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Single-target Anti-VEGF Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Single-target Anti-VEGF Drugs Price by Type (2021-2032)
  5. 11.2 Asia Single-target Anti-VEGF Drugs Market Size by Application
  6. 11.2.1 Asia Single-target Anti-VEGF Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Single-target Anti-VEGF Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Single-target Anti-VEGF Drugs Price by Application (2021-2032)
  9. 11.3 Asia Single-target Anti-VEGF Drugs Market Size by Country
  10. 11.3.1 Asia Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Single-target Anti-VEGF Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Single-target Anti-VEGF Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Single-target Anti-VEGF Drugs Market Size by Type
  2. 12.1.1 SAMEA Single-target Anti-VEGF Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Single-target Anti-VEGF Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Single-target Anti-VEGF Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Single-target Anti-VEGF Drugs Market Size by Application
  6. 12.2.1 SAMEA Single-target Anti-VEGF Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Single-target Anti-VEGF Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Single-target Anti-VEGF Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Single-target Anti-VEGF Drugs Market Size by Country
  10. 12.3.1 SAMEA Single-target Anti-VEGF Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Single-target Anti-VEGF Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Single-target Anti-VEGF Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Single-target Anti-VEGF Drugs Value Chain Analysis
  2. 13.1.1 Single-target Anti-VEGF Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Single-target Anti-VEGF Drugs Production Mode & Process
  6. 13.2 Single-target Anti-VEGF Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Single-target Anti-VEGF Drugs Distributors
  9. 13.2.3 Single-target Anti-VEGF Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst